LGALS3 and Hepatic fibrosis: Accordingly, hepatic inflammation and hepatic fibrosis were ameliorated in GLP-2-treated animals, reflected by significantly lower numbers of MAC-2-positive cells (MAC-2 immunohistochemistry) and markedly lower amount of collagen (Sirius red staining) in the livers of these mice (Figure 1A).